The structure of human chorionic gonadotrophin (hCG) is so similar to that of luteinizing hormone (LH) that a variety of assay techniques have been devised to differentiate between these two hormones. The principal indications for measurement of hCG using these methods have not changed greatly over the past decade but the improvements in the sensitivity, specificity and the development of assays for free subunits and metabolic fragments have expanded the use of hCG assays. The review discusses the use of hCG measurement in a routine clinical immunoassay laboratory and emphasizes different requirements for clinical situations.
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In recent years there have been major advances in the technology available for the measurement of human chorionic gonadotrophin (hCG) and its free subunits. Many commercial assays based on different principles are available and there is considerable confusion as to what assays should be used. This paper aims to address the following questions.
(1) How does the structure and metabolism of hCG relate to the clinical needs for measurement of this hormone? (2) with that of LH 1 -J , 5, 6 but possesses a distinctive extra 24 amino acid carboxy-terminal extension thought to have arisen by a read-through event by incorporation of an untranslated region of the stop codon of an ancestral LH gene.' In common with LH, the fl subunit possesses two arparaginelinked carbohydrate residues but also possesses four serine associated oligosaccharides that give hCG a very high carbohydrate component of its total molecular mass. 1-3, 6 Figure 3 shows the postulated structures of the Nand O-linked oligosaccharide chains on the hCG molecule. The N-glycosidic oligosaccharide unit is attached to asparagine residues 52 and 78 of hCG IX and 13 and 30 of hCG fl. Fucosylation is only seen in the fl subunit and may not be present on both chains while in the IX subunit isolated from placental heG, terminal carbohydrates are lacking from half of the 1,6 linked mannose residues.' The O-linked oligosaccharide unit is attached to residues 121, 127, 132 and 138 ofhCG fl and may also be present in O-glycosidic linkage to threonine 39 on the large free form of IX subunit produced by trophoblastic tumour cells." The high degree of sialation of the oligosaccharide chains is thought to be responsible for charge heterogeneity on isoelectric focusing. In addition the carbohydrates are also responsible for the broad band seen on SDS-PAGE and other chromatographic techniques.
Apart from the heterogeneity resulting from the oligosaccharide regions, hCG exists in dif- in placenta, serum or urine. These molecules are important as they may share or lack epitopes recognised by antibodies used for hCG measurement in the clinical laboratory. ferent molecular forms resulting from its protein core (Table 1) . Free subunits (ex and {3) are secreted in non-equimolar quantities by the placenta and tumours while high molecular mass hCG molecules and lower mass molecules such as the {3 core molecule, C terminal fragments and hCG {3 without the C terminal region are found (F-'uc)
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2) At~~~~~~~)6lTagine residues 52 and 7M of hCG bela core at:curd~g 10Slilhe and Man-GlcNAc-Gul ----... As mentioned above Fiddes et at. claimed that a single base detection in the ancestral gene for the f3 subunit of LH leads to the original 3' untranslated region now coding for the amino acids of the C terminal portion of the molecule.' There is only one IX gene described." Both subunits are formed separately, glycosylated to high carbohydrate intermediates, trimmed to the smaller oligosaccharide units and combined with the other subunits or excreted separately. Control of secretion of hCG and its subunits is not known although various investigators have attributed a stimulating role to gonadotrophic-releasing hormone (GnRH),12 corticosteroids," cyclic AMP,14 epidermal growth factor," prolactin," and a suppressive role to polyamines and the progestational steroids. I? Secretion has been alleged by some workers to be episodic with resultant variation in the circulation; 18 however, this remains controversial.
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The metabolic and renal clearance ofhCG and its subunits as determined by Wehman and colleagues l9 -21 is shown in Table 2 . The plasma clearance of hCG and subunits is multiexponential with a fast and slow component. Dissociation into subunits or removal of sialic acid markedly shortens the half-life. Disappearance of hCG from the blood and urine following term preg- 
. Relationship between blood and urine concentrations of intact hCG in pregnancy as measured by an IRMA.!J-!-'
Immunochemistry of hCG All modern clinical methods of measuring hCG depend upon immunological recognition of parts of the molecule. Knowledge of the antigenic structure and three dimensional composition of the molecule has advanced considerably with the raising of antibodies to the molecule. Antibodies to the intact molecule (tX and psubunits) almost invariably cross react with LH because of the close homology between the tX and pchains of the molecules. While rare antibodies raised to intact hCG do not cross-react with hLH and in some cases cross-reacting antibodies to LH can be Vaitukaitis and colleagues" originally raised antibodies (SB6) against the free p subunit of hCG and this has proved the standard for all subsequent antibodies. These antisera effectively distinguish hCG from LH in serum or plasma but it should be noted that many of them do show some degree of cross-reaction to LH free p subunit, do not show linear dilution in the urine or other body fluids, and have preferential specificity for the uncombined free p subunit rather than the tX-p dimer. These polyclonal antisera recognise conformational sites on the p-subunit of hCG when on the free or combined molecule." By contrast. polyclonal antisera raised against natural or synthetic carboxy terminal hCG recognise linear sequences of the p subunit and show no significant cross-reaction to the LH molecule." Unfortunately. these antisera are usually of low affinity due to the poor immunogenicity of this region and have not been introduced into clinical commercial kit assays.
The introduction of monoclonal antibodies to hCG and its free subunits has led to a revolution in the area of commercial assays for hCG and in our understanding of the immunology of the hCG molecule. Until hCG is crystallised and its three dimensional structure analysed. epitope analysis allows the best understanding of the molecular folding of this glycoprotein. A variety of publications have suggested epitope maps23.2'l.JO and the use of synthetic peptides has assisted in the localization of the binding sites of some of these monoclonal antibodies. Figure 5 shows that several groups of epitopes can be recognised to include free tX. free P. C terminal. intact hCG and several p epitopes. Monoclonal antibodies can be selected which alter the ability 2J 25 confirmed these observations ( Fig. 4 ) and in addition showed that there were very high concentrations of a p subunit-like material in the urine (subsequently shown to be p core fragment). It can be concluded from these studies that there is a semi-quantitative relationship between blood and urine values of intact hCG that makes urine testing extremely valuable for assessing whether hCG is present or absent; however quantitative measurement is preferable in the blood. Correction for creatinine concentration does not appear to make much difference to the correlation between the two fluids." of hCG to bind to its receptor and initiate a biological signal. The use of two or more monoclonal antibodies in combination can assist in the construction of assays or predefined specificity such as free IX or P subunits, Pcore, intact hCG, etc. 23 • 30 In addition, lectinmonoclonal antibody assays offer potential to combine measurement of the carbohydrate and protein composition of the hCG molecule.
Physiology of hCG in pregnancy Using the best available assays hCG is first detectable in the blood approximately 8 days after the LH peak. In the urine, Armstrong et a/. detected hCG within 9 days of ovulation." Intact hCG then increases in the serum exponentially over the next few days and is capable of linear resolution by logarithmic transformation. Once implantation is complete (II days post LH surge) the slope of the hCG rise alters from l2·4h to 30·9 h. 32 These data from Lenton and Woodward were derived using an RIA recognising the P subunit group of epitopes and since there is considerable evidence that free psubunit is increased in molar terms in early pregnancy serum," the data require confirmation using an intact hCG assay. However, early secretion of hCG leads to a rapid rise in hormone concentration to peak at between 8 and 10 weeks of pregnancy. Thereafter the intact hormone falls progressively from a maximum mean value of around l20000U/L (I st IRP) to a nadir of 10 000 U/L at the end of the second trimester. The free p subunit concentration peaks early in the pregnancy and falls rapidly while the free IX subunit concentration rises progressively throughout gestation. 23 • 33 In early pregnancy hCG concentrations double approximately every 2 days. While doubling times vary between authors and times of gestational age, the role of the rise of hCG over a short time period (24-48 h) has been a valuable test of complications in early pregnancy such as ectopic pregnancy or miscarriage. In addition, comparison of the concentration of hCG with early ultrasonic appearance of the fetus has assisted in the detection of ectopic pregnancy."
Trophoblastic tumours
Human chorionic gonadotrophin is an invaluable tumour marker in choriocarcinoma, invasive mole and hydatidiform mole. Concentrations relate directly to the number of carcinoma cells remaining and therefore indicate the response to chemotherapy and surgery. Successful response will lead to the disappearance of detectable hCG in the blood and urine; however, with the current assay sensitivity of commercial kits, many millions of tumour cells may remain after the hCG is no longer measurable. Improved assay sensitivity will permit more accurate monitoring of remaining tumour bulk. In addition to increased free p subunit secretion, altered forms of hCG, changed oligosaccharide and asialo-C terminal fragments may be found in the blood and urine of patients with choriocarcinoma. 35.36 Pbysiology of bCG secretion by nontropboblastic tissue Minute quantities of hCG are secreted from tissues other than the trophoblast and direct and indirect evidence for pituitary cell expression of the hCG gene is very strong. Concentrations of hCG are detectable in the urine of many nonpregnant patients using sensitive IRMA's and are higher following the menopause than in the reproductive years in women" presumably due to pituitary secretion. Several authors claim to be able to measure ng/L concentrations of intact hCG in the blood of non-pregnant subjects. IS Much of the hCG from pituitary cells appears to be desialated and therefore cleared from the blood compartment extremely rapidly.
There is a very large amount ofliterature relating to the presence of hCG-immunoactivity in the serum of patients with non-trophoblastic neoplasms.' Many patients with testicular tumours have high concentration of hCG,37 in particular the non-seminomatous tissue types (embryonal carcinoma, teratocarcinoma, teratoma, choriocarcinoma and yolk sac tumour), and hCG is a valuable tumour marker. In other non-testicular tumours, hCG detection varies from 0-60%; the problems of interpretation of these results are covered later.
CLINICAL INDICAnONS FOR MEASUREMENT OF bCG
There are three major reasons for a routine laboratory to receive a request for the measurement ofhCG.
The first and major reason is the detection of normal pregnancy. Pregnancy testing is performed during the investigation of amenorrhoea, for confirmation of clinical signs and symptoms of pregnancy and early detection of implantation following ovulation induction, donor insemination and in vitro fertilization. While qualitative assessment ofhCG is usually sufficient, quantitative measurement has been suggested as a valuable means of assessing early gestational age when the log value of hCG is plotted against gestational age."
Secondly, hCG has been shown to be of value in the detection and follow-up of a potentially abnormal pregnancy. Patients with ectopic pregnancy, threatened or incomplete abortion tend to have low blood concentrations of hCG for the gestational period; the time taken to double hCG levels is also prolonged." These features are particularly helpful in assessing the patient with abnormal uterine bleeding or abdominal pain when qualitative hCG measurement has shown the presence of trophoblast tissue. Quantitative evaluation of hCG in conjunction with an ultrasound scan or doubling time of the hormone are both accepted to be valuable adjuncts to assessment of the clinical and operative features.'
Thirdly, hCG measurement is extremely valuable in monitoring tumour activity, particularly gestational trophoblastic disease (choriocarcinoma, invasive mole, hydatidiform mole). These neoplasms secrete large quantities of the hormone permitting the use of hCG as a tumour marker to follow the progress of the disease. As noted previously a large number of other tumours are known to secrete hCG either as the intact molecule or as free subunits.
ASSAYS FOR bCG
The first assays for hCG were based upon bioactivity of the molecule when injected into animals. More recent bioassays have been devised that rely on in vitro stimulation of steroidogenesis from gonadal cells. As neither of these groups of assays are used in routine laboratories they will not be considered further. The first reliable in vitro qualitative tests of pregnancy were based on haemagglutination inhibition assays of urine hCG and subsequent modifications have led to specific and sensitive qualitative hCG assays (see below). Quantitative assays have been widely used for the measurement of hCG in serum and are usually based on RIA or IRMA methods (see below). The large number of antibodies and different techniques often leads to confusion as to the most appropriate assay for a laboratory.
What should be measured in an bCG assay? Intact hCG As the biologically active molecule secreted in the highest concentrations, intact hCG reflects in vivo activity most accurately. In most clinical conditions intact hCG is the major component found in the blood and most assays for hCG seek to measure this moeity either alone or in com-bination with the f3 subunit. Intact hCG is best measured by radio receptor assay (a method rarely used these days) or immunoradiometric assay (IRMA) or immunoenzymetric assays (lEMA) using antibodies directed to epitopes on the oc and f3 portions of the molecule. Because the molar concentrations of free f3 tend to be low except in tumours, f3 subunit directed antisera (so-called f3 hCG RIA) give results that are usually close to those of intact specific assays and are the commonest commercial assays available.
Free f3 subunit of hCG
The free f3 subunit of hCG IS an important marker of tumour activity in trophoblastic disease, testicular tumours and other malignancies. Molar ratios of free f3 subunit to intact hCG may be extremely high in these conditions and free f3 subunit may be detectable in the absence of intact hCG. 4lJ Attempts have been made to measure free f3 subunit indirectly by subtracting from a f3 hCG RIA (intact + f3) the intact hCG measured with a RIA or IRMA (intact HCG) but, unless there are large quantities of free f3 subunit, the amount of assay variation is sufficiently great to mask the small amount of free subunit. The alternative method is to measure the free subunit directly either by RIA or by IRMA using specific polyclonal or monoclonal antibodies that recognise epitopes that are exposed only on the free subunit. 23
• 33
Free f3 subunit is increased in early pregnancy and its measurement has been alleged to predict the outcome of pregnancy following in vitro fertilisation.P:"
Alpha subunit of hCG Free oc subunit may be measured using polyclonal or monoclonal antibodies in RIAs or IRMAs. 30 The ratio of free oc subunit to total hCG is high in late pregnancy and in some tumours. There has been a suggestion that the measurement of free oc subunit may be of value in the follow-up of patients with gestational trophoblastic disease." It should be remembered that free oc subunit is also derived from the pituitary gland and is neither placenta or tumour specific.
Beta core of hCG
Large quantities of f3 immunoreactivity are found in pregnancy urine due to the f3 core molecule (see previously)." This fragment is a very sensitive marker ofhCG secretion in normal pregnancy, ectopic pregnancy and a variety of hCG-secreting tumours even In the absence of detectable serum hCG. Because standard RIAs detect both hCG and pcore, specific IRMAs and RIAs have been developed to measure P core exclusively in the presence of large amounts of intact hCG. 23.24.44,45 The clinical importance of this molecule remains to be evaluated but holds great promise as an amplified signal of hCG secretion.
Other hCG"fragments Gel chromatography of urine has shown the presence of an Q( core molecule in normal pregnancy" and C terminal fragments in gestational trophoblastic disease. Because of the absence of any well-established clinical indications for the measurement of these molecules, there are no convenient assays available.
Combination of intact hCG, free Psubunit and f3
core fragment Many assays use antibodies with recognition of epitopes common to these three molecules following simultaneous detection of these species. This type of assay is particularly desirable in the monitoring of patients with hCG-secreting tumours.
Qualitative assays Qualitative assays for hCG give a 'yes/no' answer in those situations where the presence or absence of pregnancy needs to be ascertained. The traditional agglutination inhibition urine pregnancy tests or its modern descendants are adequate for the confirmation of normal pregnancy a few days following a missed period. Serum and urine concentrations of hCG are usually at least 200 U/L at this stage and there is little to be gained by introducing more complicated, expensive and technically demanding tests in this situation.
When low concentrations of hCG need to be detected (e.g. ectopic pregnancy, in vitro fertilization, exclusion of the possibility of pregnancy before operation or X-ray), more sensitive assays are required. Most laboratories would use a quantitative serum RIA but qualitative asays using monoclonal antibody-based 'sandwich' assays with enzymatic, fluorescent or rare earth chelate tracers can be equally valuable. We have shown that several assays based on this technology are excellent for detection of urinary hCG in ectopic pregnancy" and that they can be performed at the bedside." In particular, the Tandem Icon (Hydritech, Liege, Belgium) can be adapted to measure 1 IU /L in urine or can be made semi-quantitative or quantitative in the serum." A dipstix for use in whole blood has also been described."
Qualitative assays in pregnancy urine should theoretically measure fJ core as well as intact hCG. In practice, if the assay is sufficiently sensitive the use of an intact hCG assay appears to make no difference to the clinically diagnostic value of the procedure. There is little to be gained by trying to measure free f3 subunit in serum, except in patients with tumours, because of the very small quantities that circulate in either normal or extopic pregnancy.
Quantitative assays Radioimmunoassay
Since the early 1970s, the gold standard for the measurement of hCG has been the fJ subunit radioimmunoassay of Vaitukaitis et al." using the SB6 antibody distributed by the National Pituitary Program in the USA. This antibody detects both intact hCG and free p subunit, with a higher affinity for the latter. While crossreaction with LH is not a problem with levels normally found in the reproductive age, the high concentration in the post-menopause or following ovarian removal may interfere. In addition, the measurement of hCG in urine is less suitable because of the presence of several cross-reacting substances in this fluid. The least quantity of hCG which can reliably be detected in these assays is normally between 4 and lOU/L (lst IRP). Many enzyme and fluorescent assays of similar nature have been described which utilise antibodies derived following immunisation with free f3 subunit. Vaitukaitis has recently re-emphasized the value of this so-called 'P subunit' assay. 50
Radio-receptor assay
This assay measures intact hCG binding to corpus luteum receptors in vitro. The assay crossreacts with LH and is relatively insensitive for quantitative purposes. Despite it being a simple method of measuring potentially biologically active hCG this assay finds little use in most clinical laboratories these days.
Labelled antibody assays (Immunoradiometric assays, immunoenzymetric assays)
Two-site sandwich-type assays for intact hCG, its free subunits and fJ core have arisen following the production of high affinity monoclonal antibodies to hCG. Enhanced sensitivity (e.g. 0·04 U/L for intact hCG) and minimal crossreactivity to LH ( < 0,002%) have been reported by several authors." Other labels (enzyme, fluorescent, rare earth chelates) have been used to improve the convenience or sensitivity of these assays. Two-site assays arenot entirely free from problems, however. 'Hooking' (antigen excess causing a lower apparent result) is possible in an assay where the analyte can vary in concentration from nil to 10 7 U{L (in tumours). In addition, the problem of heterophilic antibodies (whereby certain patients have antimouse antibodiesj'l" can give false positive readings. While the cost of these techniques is still relatively high, they can be expected to become cheaper in the future as competition between manufacturers increases.
Automated assays
A variety of commercial manufacturers have automated methods for hCG measurement with varying degrees of success. Examples of these include the Encore (Baker Instruments Corp, Allentown, USA), Stratus (American Hospital Supply, Ashford, UK) and EMIT (Syva Company, Palo Alto, USA) systems. It can be expected that these will take an increasingly large market share in the future. The comparative characteristics of these assays are reviewed in Table 3 .
TECHNICAL PROBLEMS WITH bCG ASSAYS

Standardisation of bCG
Comparative evaluation of the quality of com-mercial hCG kits has been greatly hindered by the different standards for this hormone.' Unlike other hormones and drugs that can be derived synthetically, hCG and other glycoproteins, despite protein purity, are still heterogeneous with respect to carbohydrate structure and bioactivity. Therefore the use of standards based on mass has not had wide acceptance despite pleas for this from several sources.P-" The World Health Organization introduced the Second International Standard (21S) for hCG in 1964 and calibrated the material against several bioassays. Derived from pregnancy urine, the material was only about 20% pure containing subunits and P core fragment material. 55 Because it was widely available, most kit manufacturers used this material or others derived from it. In 1978 the 1st International Reference Preparation (l st IRP) was introduced for intact hCG (75{537 and 75{ 589) derived from a highly purified preparation from Columbia University and the NIH; in addition reference preparations for free oc (lRP 75{ 569) and free P (lRP 75{551) were introduced.
The Ist IRP for intact hCG contains 650IU per ampoule and has a specific activity of about 11900U per milligram of protein. Commercial hCG kit manufacturers have to use material calibrated against the 1st IRP because the original preparation is in short supply. It should be re-emphasised that both the lst IRP and 21S are based on bioassay results, accordingly immunoassays that measure only intact hCG (IRMA, lEMA, etc.) tend to give comparable (1) Altered forms of hCG: Increased molar ratio of free subunits (trophoblastic and testicular tumours)
Increased concentration of urine p core (pregnancy, tumours) (2) hCG-like substances in non-pregnant patients (3) Interference by non-hCG substances: High concentrations of LH High concentrationf of LH p subunit Other heterophilic antibodies Antibodies or binding proteins (4) Carryover by positive displacement pipettes (5) Others values regardless of the standard. By contrast assays that recognise f3 epitopes (RIA) tend to
give values approximately 50% less in the 21S than the 1st IRP because of the preponderance of free Psubunit and core fragment. Accordingly, comparative evaluation of kits for hCG and their claimed sensitivity should take into account both the assay technique and the calibration of the standard. Ideally the 1st IRP should be used.
Discordant results
The results obtained with different methods of assay for hCG may vary considerably. Hussa" has reviewed this topic and the causes are shown in Table 4 . The laboratory should be particularly cautious about hCG results in the following situations: (I) When a low positive quantitative result is obtained; i.e. quantitatively less than 200 U/L (and usually even less than 30 U/L) (2) Where dilution of the specimen yields increasingly higher results (3) Where a positive result is not consistent with the clinical and operative findings (4) Where a result is negative in at least one alternative test for hCG (5) Where hCG concentration shows no change over several days In summary, the suggested actions to resolve discordant results are shown in Table 5 .
Problems witb IRMA and IEMAs The use of IRMAs for measuring hCG has not been as popular as expected despite the obvious theoretical advantages offered. Part of this problem is due to the hooking encountered in the presence of antigen excess." While two-step assays using solid-phase antibody on ELISA plates or cellulose reduce this phenomenon considerably, a plateau may be encountered which gives rise to inaccurate results. To obviate this the following steps should be used, particularly when assaying blood from patients with hCGproducing tumours:
(1) Solid phase capture antibodies in excess with adequate washing steps are recommended (ELISA plates, cellulose, sepharose) (2) Every specimen should be diluted. This can be done without additional expense by doing two dilutions as singletons. Many IRMAs will permit use of less specimen (e.g. 100 I-lL or 20 I-lL instead of separate dilution before pipetting) (3) The analytical range of the assay can be reduced (4) Use ofa high dose of detection antibody with a low specific activity; this is well achieved in lEMA's which suffer less from the problem
RECOMMENDATIONS
With interest in hCG measurement in pregnancy and as a tumour marker, requests for assay of hCG levels are likely to increase in the future. Sensitive and specific qualitative methods of detection of this hormone should be used increasingly to make a rapid diagnosis of pregnancy. Many excellent methods are already available and techniques such as immunoconcentration allow detection to approximately 1 UIL in the presence of high concentrations of LH. Quantitation of these methods is possible using equipment similar to the glucometer (e.g. Icon QSR Hybridtech, Liege).
Quantitative assays for hCG should be sensitive and specific. In this regard the traditional B-RIA is still eminently suitable for most purposes including tumour monitoring. Labelled sandwich antibody assays (IRMA, lEMA) offer enhanced specificity and sensitivity to below 1 lUlL and are ideally suited for the measurement of tumour hCG when concentrations drop below those of the sensitivity of RIA. Ideally, each region should have a reference laboratory where RIA and IRMA assays are offered; specimens with anomalous results or very low levels should be checked by both methods. Where a laboratory offers hCG assays for tumour monitoring, some assessment of free f1 subunit of hCG should be offered either by f1 hCG RIA detecting epitopes on the f1 subunit or free f1 subunit IRMA to avoid the relatively rare situation of subunit secretion in the absence of the intact molecule. 
